Kyogoku unyu shoji
9073
BlueMeme
4069
Estore
4304
Visumo
303A
D. Western Therapeutics Institute
4576
(Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 4.93%32.86B | 9.35%129.13B | -12.34%32.24B | 6.61%32.56B | 19.91%33.01B | 34.78%31.31B | 13.81%118.09B | 43.80%36.78B | 20.24%30.54B | 0.28%27.53B |
Cost of revenue | -2.88%27.45B | 6.41%109.03B | -15.56%25.68B | 2.46%27.53B | 13.62%27.55B | 35.04%28.26B | 17.84%102.46B | 39.08%30.41B | 23.11%26.87B | 13.20%24.25B |
Gross profit | 77.36%5.41B | 28.62%20.1B | 3.00%6.57B | 37.01%5.02B | 66.38%5.46B | 32.41%3.05B | -7.04%15.63B | 71.54%6.38B | 2.69%3.67B | -45.59%3.28B |
Operating expense | 8.46%2.92B | 7.21%11.36B | 14.20%3.1B | 8.80%2.86B | 5.84%2.72B | -0.07%2.69B | 1.96%10.6B | 0.22%2.71B | 1.63%2.63B | -0.62%2.57B |
Operating profit | 601.69%2.48B | 73.78%8.73B | -5.29%3.47B | 108.17%2.17B | 284.03%2.74B | 189.85%354M | -21.63%5.03B | 262.15%3.67B | 5.47%1.04B | -79.29%714M |
Net non-operating interest income (expenses) | 25.81%-46M | -29.92%-317M | -2.68%-115M | -12.86%-79M | -60.53%-61M | -158.33%-62M | -62.67%-244M | -100.00%-112M | -42.86%-70M | 20.83%-38M |
Non-operating interest income | 29.03%40M | 16.90%83M | 28.57%9M | 15.38%15M | 3.70%28M | 29.17%31M | -51.03%71M | 16.67%7M | 8.33%13M | 22.73%27M |
Non-operating interest expense | -7.53%86M | 26.98%400M | 4.20%124M | 13.25%94M | 36.92%89M | 93.75%93M | 6.78%315M | 91.94%119M | 36.07%83M | -7.14%65M |
Net investment income | ||||||||||
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 95.64%-15M | -600.00%-15M | 0 | -107.23%-344M | -40.00%3M | 83.61%-20M | 0 | |||
Income from associates and other participating interests | -62.76%178M | 24.96%1.72B | 161.11%658M | 13.03%321M | -38.08%265M | 15.46%478M | 56.06%1.38B | -41.80%252M | 494.44%284M | 575.56%428M |
Special income (charges) | 511.11%55M | -7M | -46.67%-22M | 0.00%5M | -80.00%1M | 80.00%9M | 0 | 90.51%-15M | 0.00%5M | 0.00%5M |
Less:Restructuring and mergern&acquisition | 0.00%-5M | 0.00%-20M | 0.00%-5M | 0.00%-5M | 0.00%-5M | 0.00%-5M | 0.00%-20M | 0.00%-5M | 0.00%-5M | 0.00%-5M |
Less:Other special charges | -1,150.00%-50M | --27M | ---- | ---- | ---- | ---4M | ---- | ---- | ---- | ---- |
Less:Write off | ---- | --0 | ---- | ---- | ---- | ---- | -87.73%20M | ---- | ---- | ---- |
Other non-operating income (expenses) | 189.61%223M | 223.08%378M | 79.43%375M | 140.45%36M | -587.50%-110M | 492.31%77M | -77.63%117M | -47.22%209M | -141.98%-89M | 78.67%-16M |
Income before tax | 237.92%2.9B | 76.89%10.5B | 8.77%4.35B | 112.78%2.45B | 159.65%2.84B | 374.68%857M | -19.38%5.93B | 145.67%4B | 19.54%1.15B | -66.09%1.09B |
Income tax | 442.68%852M | 74.15%2.61B | -29.54%725M | 164.97%938M | 199.62%794M | 206.80%157M | -24.84%1.5B | 251.19%1.03B | 3.81%354M | -74.74%265M |
Net income | 192.27%2.04B | 77.80%7.88B | 22.00%3.63B | 89.46%1.51B | 147.16%2.04B | 523.64%699M | -17.34%4.43B | 122.53%2.97B | 28.34%797M | -61.96%827M |
Net income continuous operations | 192.00%2.04B | 77.82%7.88B | 22.03%3.63B | 89.57%1.51B | 146.86%2.04B | 524.24%700M | -17.34%4.43B | 122.53%2.97B | 28.18%796M | -61.91%828M |
Noncontrolling interests | -105.71%-4M | 68.16%338M | 64.38%120M | 50.00%69M | -13.19%79M | 877.78%70M | 8.65%201M | 0.00%73M | -4.17%46M | 116.67%91M |
Net income attributable to the company | 225.60%2.05B | 78.23%7.54B | 20.89%3.51B | 91.74%1.44B | 167.71%1.97B | 505.81%629M | -18.26%4.23B | 129.87%2.9B | 31.06%751M | -65.59%734M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 225.60%2.05B | 78.23%7.54B | 20.89%3.51B | 91.74%1.44B | 167.71%1.97B | 505.81%629M | -18.26%4.23B | 129.87%2.9B | 31.06%751M | -65.59%734M |
Gross dividend payment | ||||||||||
Basic earnings per share | 232.96%118.9 | 80.90%434.06 | 23.16%202.5967 | 96.48%83.6433 | 169.13%112.11 | 506.72%35.71 | -17.98%239.94 | 130.74%164.4933 | 31.71%42.57 | -65.43%41.6567 |
Diluted earnings per share | 232.28%118.58 | 80.51%433.11 | 22.83%202.05 | 95.98%83.43 | 169.94%111.9433 | 506.45%35.6867 | -17.98%239.94 | 130.81%164.4933 | 31.71%42.57 | -65.59%41.4703 |
Dividend per share | 0 | 87.14%131 | 87.14%131 | 0 | 0 | 0 | 162.50%70 | 162.50%70 | 0 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |